Cresemba under the microscope: Real-World safety check for fungal infections

NCT ID NCT04744454

Completed Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how safe and effective the drug Cresemba (isavuconazole) is for Korean patients with serious fungal infections like invasive aspergillosis or mucormycosis. Researchers tracked side effects and how well the drug worked in 94 adults. The goal was to confirm the drug's safety and effectiveness in real-world use, as required by Korean health authorities.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Isavuconazole (brand name Cresemba)
What this could lead to: If results are positive, it could confirm that Cresemba is a safe and effective option for treating serious fungal infections in Korean patients.
What could go wrong: This is an observational study, not a controlled trial, so results may be less reliable. It is also small (94 people) and only in Korea, so findings may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASPERGILLOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aspergillosis invasive aspergillosis Zygomycosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASPERGILLOSIS MUCORMYCOSIS

Contacts and locations

Locations

Pfizer Korea

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.